Skip to main content

Table 1 Clinical assessment and neuroimaging at baseline and follow-up

From: MR CLEAN, a multicenter randomized clinical trial of endovascular treatment for acute ischemic stroke in the Netherlands: study protocol for a randomized controlled trial

Baseline  
Clinical assessment Demographics, risk factors, medication, medical history, NIHSS
Neuro-imaging Unenhanced CT and CT angiography*
Follow-up  
Clinical assessment at 24 hours NIHSS. Adverse events.
Neuro-imaging at 24 hours CT angiography*
Neuro-imaging at 5-7 days Unenhanced CT or MRI
Clinical assessment at 1 week or discharge NIHSS; Barthel index
Clinical assessment at 90 days Modified Rankin score, Barthel index, EQ5D
  1. *Magnetic resonance imaging (MRI) and magnetic resonance angiography (MRA) are allowed; computed tomography (CT) perfusion is recommended but not obligatory. EQ-5D, EuroQol 5D measurement tool for health-related quality of life; NIHSS, National Institutes of Health stroke scale.